Mutation in diffuse-type gastric carcinoma identified

Professor Hiroyuki Aburatani (Genome Science) and his research group carried out genome sequencing of diffuse-type gastric carcinomas with a high probability of a poor outcome and identified mutations of the RHOA gene that are potential targets for drug treatment. The gain of new functions by the RHOA mutations identified in this study are a potential new drug target against diffuse-type gastric cancers.